Arvinas, ARV-102, Parkinson’s Disease, LRRK2, LRRK2 Degrader, PROTAC, Targeted Protein Degradation, Neurodegenerative Disease, Phase 1, Clinical Trial, Oculomotor Function

Arvinas Reports ARV-102 Phase 1 Parkinson’s Data

• By cGxPwire Editor
• October 8, 2026